Question: What the single EGFR substitution S468R does to three marketed antibodies
How often the resistance substitution appeared in patients progressing on cetuximab, and whether they responded to panitumumab
Collecting findings
0/2 publication-ready
Findings metrics
—
total
—
verified
—
pending
—
rejected